Acrivon Therapeutics, Inc. (ACRV) News
Follow Acrivon Therapeutics, Inc. (ACRV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
ACRV’s AI-driven AP3 platform targets precision drug development
ACRV says its AI-driven AP3 platform matches drug effects to disease pathways, validated in internal and in-licensed assets. Lead programs include phase II-B CHK1/2 inhibitor for serous endometrial cancer and phase II WE
EQUITY | Sep 09, 2026, 02:00 PM UTC
L
ACRV highlights AP3 AI platform for oncology drug development
ACRV says its AP3 platform supports high-resolution, AI-driven drug development, with lead assets in phase II trials and a preclinical CDK11 inhibitor targeting AML.
EQUITY | Sep 09, 2026, 01:29 PM UTC
L
Acrivon Therapeutics set to present at 2026 Cantor Global Healthcare Conference
Acrivon Therapeutics says it will present at the 2026 Cantor Global Healthcare Conference, according to the company’s announcement.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
Acrivon Therapeutics to present at 2026 Cantor Global Healthcare Conference
Acrivon Therapeutics (ACRV) plans to present at the 2026 Cantor Global Healthcare Conference.
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
Acrivon Reports Q2 2026 Financial Results
Acrivon reports second quarter 2026 financial results
EARNINGS | Aug 12, 2026, 08:07 PM UTC
M
Acrivon Advances ACR-2316 Into Randomized Dose Expansion
Acrivon starts dose expansion in phase 1/2 study
EQUITY | Aug 05, 2026, 12:30 PM UTC